LOS ANGELES–(BUSINESS WIRE)–Turn Therapeutics, a clinical-stage biotechnology company pioneering next-generation topical therapies, today announced the launch of its final crowdfund investment round in tandem with the upcoming initiation of a controlled clinical trial evaluating its flagship, non-steroidal topical platform in patients with moderate to severe eczema.

“Investment opportunities like ours are traditionally only available to venture capital funds and the ultra wealthy,” Burnam said. “This model—combining grassroots investment with the support of bigger institutions—is the future of biotech financing.”Share

Turn has also engaged Clear Street to assess pathways to the public markets as part of a broader strategic capital plan to fund late-stage trials across its therapeutic pipeline.

“We are entering one of the most exciting and consequential chapters in Turn’s history,” said Bradley Burnam, CEO of Turn Therapeutics. “With our final crowdfunding round, everyday investors have a rare opportunity to deploy capital just before major clinical readouts — and before we take on significant institutional funding.”

Turn’s upcoming trial will assess the clinical performance of its proprietary formula over an eight-week treatment period, measuring reductions in disease severity and itch. The study will include a placebo control and is designed to build upon previously reported data demonstrating the formula’s inhibition of IL-31 and IL-36 — cytokines recognized as central drivers of the eczema disease process. Turn anticipates topline data by the end of 2025.

In addition to supporting future phase 3 trials for its moderate to severe eczema candidate, proceeds from this fundraising round will advance Turn’s research program for onychomycosis, or toenail fungus.

Turn has previously secured post-public financing commitments through a $75 million equity facility with GEM, a private equity and alternative investment group.

“These investment opportunities like ours are traditionally only available to venture capital funds and the ultra wealthy,” Burnam said. “We believe this model — combining grassroots investment with the support of bigger institutions — is the future of biotech financing.”

The crowdfund campaign is now live here. More information on Turn’s clinical programs can be found at turntherapeutics.com.

For more information or to request an interview with Turn Therapeutics CEO Bradley Burnam, please contact Cooper Rumrill at (202) 980-4968 or cooper@keybridge.biz.

About Turn Therapeutics

Turn Therapeutics is a pharmaceutical and medical device organization specializing in the development of advanced wound and dermatology solutions. Utilizing its proprietary technology and patient-first approach, Turn Therapeutics addresses critical needs in healthcare, aiming to improve access, outcomes, and quality of life. Visit turntherapeutics.com to learn more about the company.

The Regulation A+ offering is made available through StartEngine Primary LLC, member FINRA/SIPC. The investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of entire investment. The statements contained herein may include prospects, statements of future expectations, and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance, or events may differ materially from those expressed or implied in such forward-looking statements.

Contacts

Cooper Rumrill
(202) 980-4968
cooper@keybridge.biz

(c)2025 Business Wire, Inc., All rights reserved.